NIAID

Category

‘Serious Quality Problems’ at Eli Lilly Production Facility Used to Produce POTUS Touted Monoclonal Antibodies

The U.S. Food and Drug Administration (FDA), not the clinical sponsor, paused a recent study based on serious quality control issues at a production facility of Eli Lilly and Co. Apparently, this plant represented one of the facilities the company was preparing to...

Lilly, NIAID & Care Access Research Transform How Studies Done to Reach Nursing Homes During COVID-19 Pandemic

On Aug. 3, TrialSite applauded the effort of  Lilly & Co. (NYSE: LLY) and the National Institute of Allergy and Infectious Diseases (NIAID) for the Blaze-2 clinical trial. Why? Because it’s one of the first, if not the first nationwide intervention during the...

ACTIV-2 Clinical Trial Comes to University of Pittsburgh School of Medicine: Investigators Test LY-CoV555 & Potentially Ab8

The University of Pittsburgh School of Medicine (Pitt) represents one of 25 initiated trial site organizations investigating novel therapies targeting the earlier stages of COVID-19 in a bid to start focusing on early treatment to reduce disease progression. Pitt has...

Atlanta’s Emory University a Hub in the War Against COVID-19 as Phase 3 mRNA-1273 Vaccine Trial First Patient Dosed

At the onset of the COVID-19 pandemic, the national research apparatus rapidly responded, mobilizing a powerful clinical trial site network known as the Vaccine Treatment and Evaluation Unit (VTEU). This is part of the National Institute of Allergies and Infectious...

University of Cincinnati Selected by NIAID as Phase III Clinical Trial Site for mRNA-1273 COVID-19 Vaccine

The University of Cincinnati (UC) has been selected by the National Institute of Allergy and Infectious Diseases (NIAID) as a clinical investigational site for the pivotal Phase III clinical trial evaluating the effectiveness of Moderna’s mRNA-1273 COVID-19...

UT Austin & VIB-led Team Identify that Special Antibody from Llama can Neutralize SARS-CoV-2 in a Cell Culture

A team of researchers out of University of Texas VIB-UGent Center for Medical Biotechnology and the National Institutes of Health (NIH) recently published a peer-reviewed study revealing that the blood from a South American camelid, the llama, could represent the path...

UC Irvine Initiates Participation in Worldwide NIAID-Sponsored Adaptive COVID-19 Clinical Trial Assessing Remdesivir (Gilead)

University of California, Irvine (UCI) joins other pathbreaking major academic centers serving as clinical investigative sites nationwide to test Gilead’s remdesivir, the novel antiviral drug developed as a treatment for the Ebola and Marburg virus. With UCI’s...

Pin It on Pinterest